Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Eli Lilly has committed $100 million in upfront and near-term payments to InnoCare Pharma to form a five-target drug discovery pact. The deal features up to $3.25 billion in milestones.
Viking Therapeutics' stock soared following the release of updated data from its obesity drug trial, indicating that trial participants mostly maintained their weight loss after switching from a weekly injection to a daily pill. In contrast, shares of competitors Eli Lilly rose while Novo Nordisk experienced a decline.
Viking Therapeutics' stock skyrocketed by 60% following the release of updated data from its obesity drug trials. The trial participants mostly kept their weight down after switching from a weight-loss drug to Viking's treatment, indicating promising results for the company's future in the obesity market.
Viking Therapeutics' stock surged by 50% following the release of updated data from its obesity drug trials. The trial participants mostly kept their weight down after switching from a weekly injection to a daily oral medication.
Viking Therapeutics Inc. shares surged after its dual-action obesity shot helped patients lose weight and keep it off, even after they cut their dosing schedule in a small, exploratory study.
Novo Nordisk A/S disappointed investors hoping for more concrete turnaround plans from Chief Executive Officer Mike Doustdar after the Danish drugmaker lost its lead in the booming obesity market to Eli Lilly & Co.
Novo Nordisk A/S disappointed investors hoping for more concrete turnaround plans from Chief Executive Officer Mike Doustdar after the Danish drugmaker lost its lead in the booming obesity market to Eli Lilly & Co.
Eli Lilly & Co. has surged about 300% since its first GLP-1 was approved over four years ago, propelling it past $1 trillion in market value and making it the world’s most valuable pharmaceutical company.
Novo Nordisk A/S will shorten its name for day-to-day use to just Novo in a bid to become more recognizable in its obesity market war with Eli Lilly & Co.
Eli Lilly & Co. has been laying the groundwork for a broader move into women’s health, assembling experts and hunting for new medicines across conditions including bone health and endometriosis, according to people familiar with the matter.
An experimental weight-loss pill from Structure Therapeutics Inc. helped patients lose as much as 16% of their body weight. This suggests it may one day compete with rivals from Eli Lilly & Co. and Novo Nordisk A/S.
Lilly has announced its acquisition of Merida Biosciences for $2.9 billion, aiming to advance treatments for serious autoimmune and allergic diseases. This deal marks Lilly's latest effort to bolster its drug pipeline focused on immune-related conditions, including Graves' disease.
FDA approves Eli Lilly's once-weekly insulin injection for type 2 diabetes
US FDA approves Lilly's once-weekly insulin injection for type 2 diabetes
China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion
Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer
Viking Therapeutics Stock Surges 36%. It Could Challenge Lilly and Novo's Obesity Empire.
US FDA approves Lilly's breast cancer drug combo
Beyond Hype: Twist Bioscience Secures Data Pipeline Role In Eli Lilly TuneLab Ecosystem
Eli Lilly Stock Gains as Retatrutide and Foundayo Data Highlight Pipeline Strength
Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs